A Phase 3 interventional study of Sodium Zirconium Cyclosilicate and Standard of care treatment (RAASi therapy) in Heart Failure and Chronic Kidney Diseases, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Recruiting at 6 sites in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia — 5 open to participants now, 6 under way, 1 of them phase 3. Heart Failure · Fundación para la Investigación del Hospital Clínico de Valencia.
Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, this one is the 5th largest by planned enrollment, is one of 5 that started in 2024, is the only one in phase 3, and was the 10th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →5 of the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia are open now, in 1 country. Recruiting first, the newest first:
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 60+ · Women only
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 94 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 64 across the 14 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fundación para la Investigación del Hospital Clínico de Valencia is the lead sponsor of 73 studies on the registry; 18 are open to participants now.
3 of the studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT06578520Fundación para la Investigación del Hospital Clínico de ValenciaEffect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | 2026-12-01 |
| NCT06992089Fundación para la Investigación del Hospital Clínico de ValenciaSHort Of Pace - Heart Failure (SHOP-HF) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and morbidity benefits. Sodium zirconium cyclosilicate (SZC) is a nonabsorbed potassium binder proven to lower serum potassium (S-K) and maintain normokalaemia. The purpose is to assess if a treatment regimen containing SZC will allow RAASi therapies to be optimized to target doses in patients with heart failure, chronic kidney disease and elevated serum potassium or at risk of developing elevated serum potassium.
This is a randomized clinical trial, multicentre, parallel group, open label, to evaluate the use of sodium zirconium cyclosilicate (SZC) to optimize RAASi therapy in patients with heart failure and chronic kidney disease, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines (1), without inducing clinically significant hyperkalemia. Eligible subjects will have been admitted to hospital because of an HF (NYHA I- III) decompensation, will have required intravenous diuretics and will have had mild hyperkalaemic values that needed stabilization or be at risk of developing hyperkalaemia. Subjects will be randomised in a 1:1 ratio to receive SZC or none (standard of care treatment without potassium binders) for 3 months while optimizing RAASi therapies according to the European Society of Cardiology (ESC) guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sodium zirconium cyclosilicate with standard of care treatment (RAASi therapy)
Drug: Sodium Zirconium Cyclosilicate
Standard of care treatment (RAASi therapy) without Sodium zirconium cyclosilicate
Drug: Standard of care treatment (RAASi therapy)
Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines
Also known as: Lokelma
Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
Number of patients increasing at least 25% of the target doses of RAASi since the screening visit (V0) to 3 months after study inclusion (V9)
To compare the number of patients achieving an increase of at least 25% of RAASi according to guideline-recommended target doses, in the arm treated with Lokelma plus RAASi versus the arm treated with RAASi without K+ binder, at 3 months after study inclusion.
Time frame: Through study completion, an average of 3 months
Number of patients achieving at least 50% of the target doses of RAASi since the screening visit (V0) to 3 months after study inclusion (V9)
To assess the number of patients achieving at least 50% of the target dose of RAASi recommended in the guidelines.
Time frame: Through study completion, an average of 3 months
Number of patients increasing 50% of RAASi doses since the screening visit (V0) to 3 months after study inclusion (V9)
To assess the number of patients achieving at least 50% of the target dose of RAASi recommended in the guidelines.
Time frame: Through study completion, an average of 3 months
Number of patients achieving at least 50% of the target doses of MRA since the screening visit (V0) to 3 months after study inclusion (V9)
To assess the number of patients that achieve at least 50% of the target dose recommended in guidelines of Mineralocorticoid receptor antagonist (MRA).
Time frame: Through study completion, an average of 3 months
Number of patients increasing 50% of MRA doses since the screening visit (V0) to 3 months after study inclusion (V9)
To assess the number of patients that achieve at least 50% of the target dose recommended in guidelines of Mineralocorticoid receptor antagonist (MRA)
Time frame: Through study completion, an average of 3 months
Number of patients achieving at least 50% of the target doses of MRA and RAASi since the screening visit (V0) to 3 months after study inclusion (V9)
To analyse the number of patients achieving at least 50% of the recommended target dose of MRA and achieving at least 50% of the guidelines recommended target dose of RAASi
Time frame: Through study completion, an average of 3 months
Number of patients increasing 50% of MRA and RAASi doses since the screening visit (V0) to 3 months after study inclusion (V9)
To analyse the number of patients achieving at least 50% of the recommended target dose of MRA and achieving at least 50% of the guidelines recommended target dose of RAASi
Time frame: Through study completion, an average of 3 months
Number of patients achieving the target doses of RAASi since the screening visit (V0) to 3 months after study inclusion (V9)
To evaluate the number of patients achieving the target dose recommended in guidelines of RAASi.
Time frame: Through study completion, an average of 3 months
Proportion of patients in each group requiring a down titration of RAASi and/or MRA over the study period
To evaluate the number of patients requiring down titration and discontinuation of RAASi and/or MRA during the study
Time frame: Through study completion, an average of 3 months
Proportion of patients in each group requiring up titration of RAASi and/or MRA following down titration of RAASi and/or MRA
To evaluate the number of patients requiring down titration and discontinuation of RAASi and/or MRA during the study
Time frame: Through study completion, an average of 3 months
Proportion of patients in each group requiring discontinuation of RAASi and/or MRA over the study period.
To evaluate the number of patients requiring down titration and discontinuation of RAASi and/or MRA during the study
Time frame: Through study completion, an average of 3 months
Number of patients achieving at least 50% of the target doses of RAASi since the screening visit (V0) to 1 month after study inclusion
To analyse the number of patients achieving 50% of target doses recommended in guidelines of RAASi at 1 month after study inclusion
Time frame: Through study completion, an average of 3 months
Number of patients increasing 50% of RAASi doses since the screening visit (V0) to 1 month after study inclusion
To analyse the number of patients achieving 50% of target doses recommended in guidelines of RAASi at 1 month after study inclusion
Time frame: Through study completion, an average of 3 months
Number of patients achieving a decrease of at least 5% in NT-proBNP levels since the baseline visit (V1) to 3 months after study inclusion (V9).
To determine surrogate short-term (90 days) efficacy objective of changes in biomarker levels (NT-proBNP and CA125) evaluated as a decrease of at least 5% from baseline to 3 months after study inclusion.
Time frame: Through study completion, an average of 3 months
Mean Change in NT-proBNP levels since the baseline visit (V1) to 3 months after study inclusion (V9).
To determine surrogate short-term (90 days) efficacy objective of changes in biomarker levels (NT-proBNP and CA125) evaluated as a decrease of at least 5% from baseline to 3 months after study inclusion.
Time frame: Through study completion, an average of 3 months
Number of patients achieving a decrease of at least 5% in CA125 levels since the baseline visit (V1) to 3 months after study inclusion (V9).
To determine surrogate short-term (90 days) efficacy objective of changes in biomarker levels (NT-proBNP and CA125) evaluated as a decrease of at least 5% from baseline to 3 months after study inclusion.
Time frame: Through study completion, an average of 3 months
Mean Change in CA125 levels since the baseline visit (V1) to 3 months after study inclusion (V9).
To determine surrogate short-term (90 days) efficacy objective of changes in biomarker levels (NT-proBNP and CA125) evaluated as a decrease of at least 5% from baseline to 3 months after study inclusion.
Time frame: Through study completion, an average of 3 months
Mean change on Systolic arterial blood pressure measurement from baseline visit (V1) to 3 months after study inclusion (V9).
To explore changes in systolic arterial blood pressure at baseline and 3 months after study inclusion.
Time frame: Through study completion, an average of 3 months
Mean change from baseline visit (V1) measured at 3 months after study inclusion (V9) in the overall summary score of KKCQ, as a specific HF patient reported outcome questionnaire.
To explore the effect of treatment with SZC versus none on Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score.
Time frame: Through study completion, an average of 3 months
To determine the change in renal function the Mean Change in UACR and Mean change in HCO3 will be calculated between baseline visit (V1) and 3 months after study inclusion (V9)
To evaluate changes in renal function at baseline and 3 months after study inclusion between both groups
Time frame: Through study completion, an average of 3 months
Number of patients decreasing at least 40% the eGFR since the screening visit (V0) to 3 months after study inclusion (V9).
To analyse the number of patients that decrease at least 40% in estimated glomerular filtration rate (eGFR) by the CDK-EPI formula.
Time frame: Through study completion, an average of 3 months
Mean change from baseline visit (V1) measured at 3 months after study inclusion (V9) in the overall summary score of KDQoL, as a specific CKD patient reported outcome questionnaire.
To explore the effect of treatment with SZC versus none on the Kidney Disease Questionnaire of life (KDQoL) Overall Summary Score.
Time frame: Through study completion, an average of 3 months
Number of visits for HF/HK/impaired renal function/hypertension or hyperkalemia diagnosed in the outpatient clinic.
To determine the number of visits to the emergency department for HF/HK/impaired renal function/hypertension (defined as BP over 200 and/or 100 mmHg) and hyperkalemia diagnosed in the outpatient clinic.
Time frame: Through study completion, an average of 3 months
Proportion of patients requiring hospitalization for HF/HK/impaired renal function over the study period.
To analyse the number of admissions for HF/HK/impaired renal function.
Time frame: Through study completion, an average of 3 months
Mean number of hospitalizations per patient for HF/HK/impaired renal function over the study period.
To analyse the number of admissions for HF/HK/impaired renal function.
Time frame: Through study completion, an average of 3 months
Proportion of patients presenting at least one clinical event over the study period
To evaluate in both experimental groups the combined endpoint of visits to the emergency department or admission for HF/HK/impaired renal function or decrease of at least 40% in estimated glomerular filtration rate (eGFR) by the CDK-EPI formula or death from cardiovascular causes.
Time frame: Through study completion, an average of 3 months
Proportion of patients presenting more than one clinical event over the study period
To evaluate in both experimental groups the combined endpoint of visits to the emergency department or admission for HF/HK/impaired renal function or decrease of at least 40% in estimated glomerular filtration rate (eGFR) by the CDK-EPI formula or death from cardiovascular causes.
Time frame: Through study completion, an average of 3 months
Proportion of patients presenting all clinical events over the study period
To evaluate in both experimental groups the combined endpoint of visits to the emergency department or admission for HF/HK/impaired renal function or decrease of at least 40% in estimated glomerular filtration rate (eGFR) by the CDK-EPI formula or death from cardiovascular causes.
Time frame: Through study completion, an average of 3 months
Percentage of patients treated with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors over the study period in both arms
To analyse the percentage of patients with HF treated with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Time frame: Through study completion, an average of 3 months
Mean Change in Mg levels since the baseline visit (V1) to 3 months after study inclusion (V9).
To explore changes in Mg levels at baseline and 3 months after study inclusion.
Time frame: Through study completion, an average of 3 months
Proportion of patients presenting each clinical outcome over the study period: Adverse events, Serious adverse events, Changes in clinical laboratory parameters, Changes in vital signs and ECGs
To evaluate the safety and tolerability of SZC in this patient population.
Time frame: Through study completion, an average of 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 26 months is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate
Fundación para la Investigación del Hospital Clínico de Valencia